SCHEMBL4599845

SCHEMBL4599845

CCOC(C)(OC)OC(C)(OC)OCC

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
TSHR P16473 2/20 0.36
TDP1 Q9NUW8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419791 0.88
SCHEMBL3923279 0.88 ALDH1A1 (0.40) ALDH1A1TSHRTDP1
SCHEMBL3186347 0.84 TSHR (0.38) TSHRTDP1
SCHEMBL9737323 0.82 ALDH1A1 (0.44) ALDH1A1TSHR
SCHEMBL11449186 0.80 ALDH1A1 (0.35) ALDH1A1TSHRTDP1
SCHEMBL8672445 0.78 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL4966512 0.78
SCHEMBL2782256 0.78
SCHEMBL40105 0.77 TSHR (0.33) ALDH1A1TSHRTDP1
SCHEMBL663289 0.76 ALDH1A1 (0.32) ALDH1A1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426617-B2 Asymmetric hydrogenation of alkenes using chiral iridium complexes DSM IP ASSETS B.V. (NL) 2013-04-23 US claimed
WO-2025090587-A1 CANNABINOIDS COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURONAL DISORDERS INMED PHARMACEUTICALS INC. (CA) 2025-05-01 WO disclosed
WO-2025090133-A1 COMPOSITIONS AND METHODS FOR USE OF CANNABINOL COMPOUNDS IN NEUROPROTECTION INMED PHARMACEUTICALS INC. (CA) 2025-05-01 WO disclosed
EP-3684353-A1 TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN Inmed Pharmaceuticals Inc. (CA) 2020-07-29 EP disclosed
WO-2019056123-A1 TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN INMED PHARMACEUTICALS INC. (CA) 2019-03-28 WO disclosed
EP-3452036-A1 USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS Inmed Pharmaceuticals Inc. (CA) 2019-03-13 EP disclosed
WO-2017190249-A1 USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS INMED PHARMACEUTICALS INC. (CA) 2017-11-09 WO disclosed
US-20080200732-A1 Novel Intermediates Useful for the Preparation of Coenzymes, Process for the Preparation of Novel Intermediates and an Improved Process for the Preparation of Coenzymes NICHOLAS PIRAMAL INDIA LIMITED (IN) 2008-08-21 US disclosed
EP-1910263-A2 NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF COENZYMES, PROCESS FOR THE PREPARATION OF NOVEL INTERMEDIATES AND AN IMPROVED PROCESS FOR THE PREPARATION OF COENZYMES Nicholas Piramal India Limited (IN) 2008-04-16 EP disclosed
WO-2007004091-A2 NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF COENZYMES, PROCESS FOR THE PREPARATION OF NOVEL INTERMEDIATES AND AN IMPROVED PROCESS FOR THE PREPARATION OF COENZYMES NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200732-A1 Novel Intermediates Useful for the Preparation of Coenzymes, Process for the Preparation of Novel Intermediates and an Improved Process for the Preparation of Coenzymes NDUFA10, NDUFA9, NDUFB10 ALDH1A1 536/4885TSHR 4621/4885TDP1 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.